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In this paper, a very simple and facile approach for the large scale synthesis of uniform and size-
controllable single-domain magnetite nanoparticles is reported. These magnetite nanoparticles were
synthesized via thermal decomposition of a ferric nitrate/ethylene glycol solution. The structural and
morphological properties of the synthesized nanoparticles were carefully studied. Nearly spherical
nanoparticles with inverted spinel structure and average particle and crystallite sizes smaller than
20 nm were obtained. The magnetic measurements revealed that magnetite nanoparticles have a
magnetic saturation value near that of the bulk magnetite. The erythrocyte cytotoxicity assays showed
no hemolytic potential of the samples containing magnetite nanoparticles, indicating no cytotoxic
activity on human erythrocytes, which makes these interesting for biotechnological applications.
& 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
In the recent years, many researchers have investigated
materials designed to accomplish multiple performance objec-
tives using a single system [1,2], i.e., materials with multiple
functionalities for their applications in electronics, energy, and
medicine [3–6]. With the advancement in nanotechnology it has
become possible to fabricate, characterize, and specially tailor the
multifunctional properties of nanoparticles. For example, in
biomedical applications, water or alcohol dispersible magnetic
nanoparticles allowed new opportunities as contrast agents for
magnetic resonance imaging [7], magnetic ﬁeld guided drug
delivery [8], tumor treatment via hyperthermia[9] and biomole-
cular separation, and diagnostic imaging [10,11]. Especially in
drug delivery applications, drug transport through magnetic
nanoparticles has been widely studied in an attempt to obtain
particles with high drug carrier capacity, good stability in aqueous
solutions, and good biocompatibility with cells and tissues [12].
A variety of magnetic nanoparticles composed of different
atoms or ions with different magnetic moments have been
synthesized to target these applications. Inorganic nanoparticles
such as Fe3O4 (magnetite), g-Fe2O3 (maghemite), and spinel-
structured magnetic nanoparticles (MFe2O4, M¼Fe, Co, Ni, andx: þ55 44 3263 4623.
sevier OA license.Mn) have been widely used for their applications in nanomedi-
cine [13]. Among various magnetic nanoparticles, magnetite
offers many attractive possibilities in biomedine and thus is of
great importance [12]. Bulk and nanostructured magnetites
crystallize with inverted spinel structure (space group Fd3¯m)
and the large oxygen ions are closely packed in a cubic arrange-
ment, while smaller Fe-ions ﬁll the structural gaps (tetrahedral
and octahedral sites). The tetrahedral and octahedral sites form
two magnetic sublattices, A and B, respectively. This particular
arrangement of cations in A and B sublattices characterizes the
inverse spinel structure. With negative AB exchange interactions,
the net magnetic moment of the magnetite is due to the B-site
Fe2þ ions [14].
The magnetite nanoparticles have a controllable size ranging
from a few nanometers up to tens of nanometers, which is
comparable to the dimensions of some cells (10–100 mm), viruses
(20–450 nm), proteins (5–50 nm), or genes (2 nm wide and
10–100 nm long). This means that these nanoparticles are of
great interest for their use with the biological entities of interest
since they are biocompatible and able to interact or bind to target
cells [13,15,16]. To date, several methods have been proposed to
synthesize magnetite nanoparticles [17–24]. In general, these
methods are wet chemical routes. The most widely used method
is based on the co-precipitation of Fe2þ and Fe3þ aqueous salt
solutions by addition of a base [17]. The size, shape, and
composition of synthesized nanoparticles depend on the type of
salts used (chlorides, sulphates, nitrates, etc.), Fe2þ/Fe3þ ratio,
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disadvantage of this method is that the synthesis of particles must
be done in an oxygen-free environment [20]. Other methods
based on the precipitation principle have been developed: sol–
gel [21], polymer matrix-mediated synthesis [5], and precipita-
tion using microemulsions [22,23] and vesicles [24]. In all these
routes, just small quantities of nanoparticles can be produced.
Herein, we report a very simple and facile approach for the
large scale synthesis of uniform and size-controllable single-
domain magnetite nanoparticles with diameters smaller than
20 nm. Structural, microstructural, and magnetic properties of
these nanoparticles are presented and discussed. Attestation of
potential for biological applications was obtained by erythrocyte
cytotoxicity assays that showed no hemolytic potential and
negligible toxicity for samples containing magnetite nanoparti-
cles processed by the innovative route proposed in this work.2. Experimental
2.1. Preparation of magnetite nanoparticles
The magnetite nanoparticles were synthesized via thermal
decomposition of a ferric nitrate/ethylene glycol solution—see
Fig. 1(a). First, a mixture of adequate amounts of ferric nitrate
(Alfa Aesar) and ethylene glycol (Vetec) was prepared. The
solution was homogenized for 1 h, at room temperature followed
by heating at 90 1C (Fig. 1(b)). To obtain nanoparticles with
different sizes and distributions, the resulting material was
heated in a tube furnace at temperatures between 300 1C (sample
MAG300) and 500 1C (sample MAG500), under inert atmosphere
(argon)—Fig. 1(c) and (d). Results from other samples were not
included because they are similar to those of the above men-
tioned samples.
2.2. Characterization of nanoparticles
X-ray diffraction (XRD) measurements were performed with a
Shimadzu XRD 7000 diffractometer, using CuKa radiation. The
mean crystallite sizes were calculated from the linewidth broad-
ening relative to a LaB6 standard using Scherrer’s formula [25].
Morphological characterizations were conducted in a JEOL JEM-
1400 Transmission Electron Microscope (TEM) in order to gain
some insights of the microstructure and the particle sizes dis-
tribution. Temperature dependent and ﬁeld dependent magnetic
characterizations (at 300 K) were performed in a commercial
Vibrating Sample Magnetometer (VSM) from Lakeshore and in a
VSM attached with a Physical Property Measurement System
from Quantum Design.
2.3. Preparation of erythrocyte suspensions
The in vitro cytotoxic effects of magnetite nanoparticles were
studied using heparinized venous blood samples collected from
healthy volunteers. Whole blood was centrifuged (4000 rpm forFig. 1. A schematic of the ﬂowchart for the5 min) at 4 1C using a refrigerated centrifuge and the plasma and
buffy coat were removed by aspiration. The red blood cells were
washed three times by centrifugation (4000 rpm for 5 min) in
cold phosphate buffer saline (PBS; 0.15 mM NaCl, 10 mM sodium
phosphate, pH 7.4). The supernatant and buffy coat of white cells
was carefully removed with each wash. The red blood cells were
ﬁnally resuspended with the same buffer to obtain a hematocrit
of 1% [26]. This suspension was used for erythrocyte hemolysis
and measurement of Kþ assays. All experiments involving human
blood were approved by the Ethics Committee of the Universi-
dade Estadual do Centro-Oeste (protocol 313/2010).
2.4. Erythrocyte hemolysis assay
Different concentrations of MAG300 and MAG500 nanoparti-
cles were incubated with a 1% red blood cell suspension for 24 h
at 37 1C with constant shaking, in PBS with 30 mg/mL penicillin
and 50 mg/mL streptomycin solution. After incubation, the red
blood cell suspension was centrifuged at 4000 rpm for 5 min.
Hemolysis was determined by measuring the absorbance at
540 nm in a microplate reader (UV–vis spectrometer Molecular
Devices SpectraMax 190) [27,28].
2.5. Kþ release
Red blood cells were incubated with different concentrations
of MAG300 and MAG500 nanoparticles for 24 h at 37 1C with
constant shaking. After the incubation, the red blood cells were
centrifuged at 4000 rpm at 4 1C for 5 min, and Kþ release was
measured with an ion-selective electrode (Roche/AVL 9180).3. Results and discussion
3.1. Physical properties—structural, microstructural, and magnetic
properties
The XRD results (y–2y scans) for MAG300 and MAG500
samples (Fig. 2) showed broadened lines, which were assigned
to the crystallized magnetite (JCPDS PDF19-0629) with inverted
spinel structure (space group Fd3¯m) [14]. The mean crystallite
sizes (t) obtained using Scherrer’s formula [25] (t¼0.9l/B cos y,
where B is the half-value breadth of the diffracted X-ray beam, y
is the Bragg angle, and l is the wavelength of the incident X-rays)
were tMAG300¼15 nm and tMAG500¼20 nm for 300 1C and 500 1C
annealed samples, respectively.
TEM images for MAG300 and MAG500 nanoparticles are
shown in Fig. 3(a) and (b), respectively. In both samples, the
majority of the particles were nearly spherical in shape. Some
magnetite nanoparticles are partially superimposed onto the
agglomerate core, i.e., the boundary limit of each nanoparticle is
partially diffuse; thus a precise average particle size cannot be
determined. However, a narrowed particle sizes distribution can
be seen and the average particle size for the magnetite nanopar-
ticles was found to be between 15 and 20 nm. It should be notedsynthesis of magnetite nanoparticles.
Fig. 2. X-ray diffraction patterns for the magnetite nanoparticles synthesized at
(a) 300 1C (MAG300) and (b) 500 1C (MAG500). M¼magnetite (JCPDS PDF19-
0629).
Fig. 3. Transmission electron microscopy images of magnetite nanoparticles
synthesized at (a) 300 1C (MAG300) and (b) 500 1C (MAG500).
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ments tend to agglomerate with the neighboring ones, which
could be due to the substantial built-up speciﬁc surface area of
the nanosized particles [29]. Also, the magnetic nanoparticles
aggregated together to reduce their surface energy [30] and/or
due to the magnetic dipole–dipole interactions and the van der
Waals forces between the nanoparticles [31,32].
Fig. 4 plots the magnetization vs. applied ﬁeld (M vs. H) curves
for MAG300 and MAG500 samples and the value of saturation
magnetization (MS) was found to be 11 emu/g for MAG300 and
67 emu/g for MAG500. MS was found to increase with an increase
in the annealing temperature and approached that of the bulk
magnetite (92 emu/g) [12]. The increase of MS can be explained
by considering that the annealing contributes to facilitate the
exchange interaction between the magnetic sublattices of the
magnetic core (Fe3O4) and to increase the magnetic core, reducing
the surface spin effects [14]. In order to better deﬁne the magnetic
state of the magnetite nanoparticles, ﬁeld cooling (FC) and zero
ﬁeld cooling (ZFC) magnetization values were measured (as
shown in Fig. 5). All measurements were performed with an
applied DC ﬁeld of 20 Oe. No thermoremanent behavior was
observed in these curves of both samples, as previously reported
[14]. In fact, nanosized magnetic particles are expected to be
magnetic monodomain particles and the temperature depen-
dence of the thermoremanent magnetization directly correlates
with the deblocking process that occurs inside the magnetic
nanoparticle system for temperature increases in zero applied
magnetic ﬁelds and after a previous FC process. As previously
reported [14,33], the blocking temperature (TB) that was obtained
from the temperature dependent ZFC and FC curves was near
room temperature. This behavior is expected since the magnetic
properties of nanoparticles are strongly inﬂuenced by ﬁnite size
effects and the breaking of the crystal symmetry at the particlesurface. In that case, very high anisotropy constant values sup-
press the thermoremanent behavior [14].3.2. Cytotoxicity assays
Magnetite nanoparticles have been of signiﬁcant use for many
different technological areas, especially in biomedical applica-
tions. However, for use in biological systems they should have
biocompatibility with cells and tissues among other properties.
Several tests have been performed in order to evaluate the
toxicological risks of magnetite nanoparticles [34], including the
evaluation of cytotoxicity on red blood cells and phagocyte cells
[35–38].
Fig. 4. Room temperature magnetization vs. magnetic ﬁeld data (M vs. H) of
magnetite nanoparticles synthesized at (a) 300 1C (MAG300) and (b) 500 1C
(MAG500).
Fig. 5. Temperature dependent magnetization (ﬁeld cooling and zero ﬁeld cool-
ing) of magnetite nanoparticles synthesized at (a) 300 1C (MAG300) and (b) 500 1C
(MAG500).
Fig. 6. Hemolysis test on human erythrocytes with increasing concentrations of
magnetite nanoparticles synthesized at (a) 300 1C (MAG300) and (b) 500 1C
(MAG500).
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cytotoxicity of a series of compounds that have some potential
biological activity and that have not yet been evaluated for toxic
effects by other methods. Hemolysis testing is a fast, efﬁcient,
simple, and low cost analysis method to evaluate the possible
cytotoxicity of magnetite nanoparticles on erythrocytes mem-
brane, determined spectrophotometrically by observing the
release of hemoglobin. Fig. 6 shows representative results
obtained by spectroscopic measurements. The incubation (sus-
pension of cells in saline with some volume of magnetite
nanoparticles) for 24 h with different concentrations of MAG300
and MAG500 (0.062–1.87 mg/mL) promoted a rate of hemolysissimilar to that of control sample (suspension of cells in the
absence of nanoparticles), i.e., MAG300 and MAG500 nanoparti-
cles promoted no signiﬁcant hemolysis in these blood cells.
Corroborating with hemolysis results, the analysis of K-release
of red blood cells, which is also an indicator of membrane
damage, showed similar results (data not shown). Thus, the
cytotoxicity assays results indicate that MAG300 and MAG500
nanoparticles have no effects on blood cells that were potentially
in contact with these particles in circulation, demonstrating their
potentiality for nanomedicine and biotechnological applications.4. Conclusion
In this study, we report a very simple approach for the large
scale synthesis of uniform and size-controllable single-domain
magnetite nanoparticles. Based on of X-ray diffraction and trans-
mission electron microscopy, it was inferred that the magnetite
nanoparticles were of spherical shape with diameters smaller than
20 nm and narrow size distribution. Magnetic saturation close to
the bulk magnetite was conﬁrmed with magnetic measurements.
Assays using human erythrocytes were performed to evaluate the
cytotoxicity of these magnetite nanoparticles. The erythrocyte
cytotoxicity assays showed no hemolytic potential of the samples
containing magnetites. Thus, we can conclude that the magnetite
nanoparticles have no cytotoxic activity on human erythrocytes.
These results clearly indicate that the present magnetite
nanoparticles can be a model drug-carrier, which makes these
interesting for their potential use in other biomedical applica-
tions, such as DNA separation, drug delivery site-speciﬁc, cancer
treatment by hyperthermia, and diagnostic imaging in MRI.
L.F. Co´tica et al. / Journal of Magnetism and Magnetic Materials 324 (2012) 559–563 563Further, this new route of nanoparticles synthesis would simplify
and reduce the cost of production, providing access to drugs and
carriers that utilize these nanoparticles to a large number of
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